Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...

(Reuters) -British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in ...

More than 15 million people in the U.S. are affected by COPD (chronic obstructive pulmonary disease), a condition that damages the lungs and makes it hard to breathe. 1 But a diagnosis doesn’t have to ...

On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...

Theravance Biopharma TBPH recently announced that it has entered into a definitive agreement with Royalty Pharma RPRX to sell all of the former’s equity interests in Theravance Respiratory Company LLC ...

Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

(Reuters) - British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The dispute centered on how to use royalties from the ...

If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan ...